Search Result

Results for "

P2Y

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P2Y Receptor (112) 5-HT Receptor (1) Apoptosis (4) Arrestin (2) Autophagy (1) Calcium Channel (1) Cytochrome P450 (3) DNA/RNA Synthesis (3) Drug Metabolite (3) Endogenous Metabolite (18) ERK (2) Isotope-Labeled Compounds (6) Na+/Ca2+ Exchanger (1) Necroptosis (1) NF-κB (3) NOD-like Receptor (NLR) (1) P2X Receptor (6) Reactive Oxygen Species (1)
By Research Areas:	Cancer (21) Cardiovascular Disease (56) Infection (1) Inflammation/Immunology (37) Metabolic Disease (14) Neurological Disease (13)
Oligonucleotides:	Nucleotides and their Analogs (2)

125

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: P2Y Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-149454

P2Y1/P2Y12 antagonist-1	P2Y Receptor	Cancer
P2Y1/P2Y12 antagonist-1 (compound 24w) is an orally available dual inhibitor of *P2Y1* and *P2Y12* with antiplatelet activity. P2Y1/P2Y12 antagonist-1 inhibits ADP-induced platelet aggregation in rabbit plasma with an IC₅₀ of 4.23 μM. P2Y1/P2Y12 antagonist-1 exhibits potent inhibitory effects in rat thrombosis model.

HY-146486

P2Y2R/GPR17 antagonist 1	P2Y Receptor	Inflammation/Immunology
P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual *P2Y₂R* and GPR17 antagonist with IC₅₀ values of 3.17 µM and 1.67 µM against P2Y₂R and GPR17, respectively. P2Y2R/GPR17 antagonist 1 shows excellent metabolic stability in human liver microsomes .

HY-168098

P2Y6R antagonist 1	P2Y Receptor	Inflammation/Immunology
P2Y6R antagonist 1 (compound 5ab) is a selective, orally active *P2Y6R* antagonist with an IC₅₀ value of 19.6 nM. P2Y6R antagonist 1 has anti-inflammatory activity .

HY-163645

P2Y12 antagonist 1	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .

HY-162661

P2Y14R antagonist 2	P2Y Receptor	Inflammation/Immunology
P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active *P2Y14R* antagonist with an IC₅₀ value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis .

HY-161727

P2Y14R antagonist 1	P2Y Receptor NOD-like Receptor (NLR)	Inflammation/Immunology
P2Y14R antagonist 1 (compound I-17) is a selective *P2Y14R* antagonist with an IC₅₀ of 0.6 nM. It exhibits potent *P2Y14R* antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .

HY-108671

NF110	P2X Receptor	Neurological Disease
NF110 is a *P2X₃* receptor antagonist (K_i = 36 nM) and inactive toward P2Y receptors stably expressed (IC₅₀s > 10 M). NF110 blocks alphabeta-methylene-ATP-induced currents (IC₅₀ = 527 nM) in rat dorsal root ganglia neurons .

HY-111064

BX 667	P2Y Receptor	Cardiovascular Disease
BX 667 is an orally active reversible P2Y(12) receptor antagonist. BX 667 attenuates thrombosis .

HY-134369

Ap4C tetrasodium	P2Y Receptor	Others Inflammation/Immunology
Ap4C tetrasodium is a dinucleoside polyphosphate containing purine and pyrimidine base moieties. Ap4C tetrasodium acts as a signaling molecule by binding to specific *P2Y* receptors, activating *P2Y2* and *P2Y4* receptors in platelets, leading to platelet aggregation and other cellular responses. Ap4C tetrasodium can be used for research in inflammation and blood coagulation .

HY-129576

PSB-16133 sodium	P2Y Receptor	Inflammation/Immunology
PSB-16133 (sodium) is a tool compound specifically designed to block P2Y receptor subtypes .

HY-137602

P1,P2-Diuridine-5’-diphosphate Up2U	P2Y Receptor	Others
P1,P2-Diuridine-5’-diphosphate (Up2U) is a symmetrical dinucleoside polyphosphate containing two pyrimidine base moieties. P1,P2-Diuridine-5’-diphosphate is also an activator of purinergic P2Y receptor .

HY-137418

2-MeS-ATP 2-Methylthio-ATP	P2Y Receptor	Others Inflammation/Immunology
2-MeS-ATP (2-Methylthio-ATP) is an analog of adenosine nucleotides and acts as a P2Y purinergic receptor agonist specific for adenosine nucleotide activation. 2-MeS-ATP is also able to inhibit the release of toxic mediators from macrophages stimulated by endotoxin (LPS). 2-MeS-ATP can be used in the study of endotoxin shock and inflammatory diseases .

HY-122211

MRS2802	Endogenous Metabolite	Cardiovascular Disease
MRS2802 is a P2Y14 receptor agonist with an EC50 value of 63 nM. MRS2802 can effectively activate the P2Y14 receptor and may play a role in regulating platelet function. The selectivity and activity of MRS2802 are conducive to in-depth research on the biological functions and pharmacological properties of P2Y receptors. The development of MRS2802 provides a potential inhibitory strategy for the search for new antiplatelet compounds .

HY-108662

PIT 2,2'-Pyridylisatogen tosylate	P2Y Receptor	Inflammation/Immunology Cancer
PIT (2,2'-Pyridylisatogen tosylate) is a selective and non-competitive antagonist of P2Y1 receptor with an IC₅₀ value of 0.14 μM for human P2Y1 receptor. PIT antagonizes P2Y1 receptor signaling without affecting nucleotide binding. PIT is an irreversible antagonist of responses to ATP at metabotropic purinoceptors (of the P2Y family) in some smooth muscles. PIT can be used for the research of chronic bronchitis and asthma ^[2] .

HY-117572

MRS2567	Others	Others
MRS2567 is a P2Y receptor antagonist with the activity of inhibiting contraction of mouse mesenteric arteries. MRS2567 can inhibit the sustained contraction caused by UTP and UDP, and inhibit the Na?, K?, 2Cl? co-transport-dependent signaling pathway, thereby affecting the myogenic tone of mouse mesenteric arteries.

HY-108648

2-MeS-ADP trisodium 2-Methylthioadenosine diphosphate trisodium; 2-Methylthio-ADP trisodium	P2Y Receptor	Neurological Disease
2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 ^[2] .

HY-108648A

2-MeSADP 2-Methylthioadenosine diphosphate; 2-Methylthio-ADP	P2Y Receptor	Neurological Disease
2-MeSADP (2-Methylthioadenosine diphosphate; 2-Methylthio-ADP) is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-MeSADP has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-MeSADP induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 ^[2] .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 22 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits *CYP2B6* and *CYP2C19* with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ^[2]．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-17459S

Clopidogrel-d3 hydrogen sulfate (S)-(+)-Clopidogrel bisulfate-d₃; (S)-(+)-Clopidogrel-d₃ hydrogen sulfate	P2Y Receptor Cytochrome P450	Cardiovascular Disease
Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-17459R

Clopidogrel hydrogen sulfate (Standard) (S)-(+)-Clopidogrel bisulfate (Standard); (S)-(+)-Clopidogrel hydrogen sulfate (Standard)	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (hydrogen sulfate) (Standard) is the analytical standard of Clopidogrel (hydrogen sulfate). This product is intended for research and analytical applications. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits *CYP2B6* and *CYP2C19* with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ^[2]．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-108663

5-OMe-UDP 5-Methoxyuridine 5'-trihydrogen diphosphate	P2Y Receptor	Neurological Disease Metabolic Disease
5-OMe-UDP (5-methoxyuridine 5'-trihydrogen diphosphate) is a *P2Y6* receptor agonist (EC₅₀=0.08 μM). 5-OMe-UDP activates the *P2Y6* receptor by binding to it, which triggers signaling pathways within the cell. This activation can lead to an increase in intracellular calcium ion concentration, which in turn regulates cellular function. The methoxy groups of 5-OMe-UDP provide additional activity and selectivity, contributing to the binding of 5-OMe-UDP to the *P2Y6* receptor. 5-OMe-UDP can be used to study diseases related to *P2Y6* receptor function, such as diabetes, inflammatory bowel disease, Alzheimer's disease, etc .

HY-113044

Uridine diphosphate glucose	Endogenous Metabolite P2Y Receptor	Metabolic Disease
Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y₁₄ receptor, a neuroimmune system GPCR ^1.

HY-113044R

Uridine diphosphate glucose (Standard)	P2Y Receptor Endogenous Metabolite	Metabolic Disease
Uridine diphosphate glucose (Standard) is the analytical standard of Uridine diphosphate glucose. This product is intended for research and analytical applications. Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y₁₄ receptor, a neuroimmune system GPCR ^[2].

HY-110322A

PPTN 2 Publications Verification	P2Y Receptor	Inflammation/Immunology
PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .

HY-110322

PPTN hydrochloride 2 Publications Verification	P2Y Receptor	Inflammation/Immunology
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .

HY-103055

PPTN mesylate	P2Y Receptor	Inflammation/Immunology
PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .

HY-13104

MRS 2578 5+ Cited Publications	P2Y Receptor Apoptosis	Cardiovascular Disease
MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC₅₀s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors ^[2].

HY-108650

2-Thio-UTP tetrasodium 2-Thiouridine 5′-triphosphate tetrasodium	P2Y Receptor	Cancer
2-Thio-UTP tetrasodium is a potent *P2Y₂, P2Y₄* and *P2Y₆* agonist, which an be used for the research of cancer .

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive *P2Y1* receptor antagonist, with a K_b of 102 nM and a *pA₂* of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors ^[2]. MRS2179 tetrasodium inhibits platelet aggregation .

HY-101308A

MRS2179 tetrasodium hydrate 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive *P2Y1* receptor antagonist, with a K_b of 102 nM and a *pA₂* of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors ^[2]. MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-137955

MRS 2211 sodium hydrate	P2Y Receptor	Cardiovascular Disease Others Neurological Disease
MRS 2211 sodium hydrate is a competitive *P2Y13* receptor antagonist (pIC₅₀= 5.97). MRS 2211 sodium hydrate is highly selective to the *P2Y13* receptor, showing more than 20-fold selectivity compared to the P2Y1 and P2Y12 receptors. MRS 2211 sodium hydrate can be used to further investigate the role of the *P2Y13* receptor in different physiological and pathological processes, such as its function in blood cells, the nervous system and the immune system .

HY-123202

MRS2603	P2Y Receptor	Cancer
MRS2603 is a pyridoxal derivative. MRS2603 antagonized both P2Y1 and P2Y13 receptors .

HY-113359

Uridine 5'-diphosphate	P2Y Receptor Endogenous Metabolite	Others
Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor .

HY-137612

Sp-UTP-α-S Uridine 5'-O-1-thiotriphosphate	P2Y Receptor	Cancer
Sp-UTP-α-S is a *P2Y2* and *P2Y4* receptor activator. Sp-UTP-α-S can be used in cancer research .

HY-110092A

PSB-1114 triethylamine	P2Y Receptor	Cancer
PSB-1114 triethylamine is a potent, enzymatically stable, and subtype-selective *P2Y₂* receptor agonist with an EC₅₀ of 134 nM. PSB-1114 triethylamine displays >50-fold selectivity versus the *P2Y₄* (EC₅₀ of 9.3 μM) and *P2Y₆* (EC₅₀ of 7.0 μM) receptors .

HY-110092

PSB-1114 tetrasodium	P2Y Receptor	Metabolic Disease
PSB-1114 tetrasodium is a potent, enzymatically stable, and subtype-selective P2Y₂ receptor agonist with an EC₅₀ of 134 nM. PSB-1114 tetrasodium displays >50-fold selectivity versus the P2Y₄ (EC₅₀ of 9.3 μM) and P2Y₆ (EC₅₀ of 7.0 μM) receptors .

HY-108672

NF157	P2Y Receptor	Inflammation/Immunology
NF157 is a highly selective nanomolar *P2Y11* antagonist with a pK_i of 7.35. The IC₅₀s are 463 nM, 1811 µM, 170 µM for P2Y11 (K_i=44.3 nM), P2Y1 (K_i=187 µM), P2Y2 (K_i=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) ^[2].

HY-108651

Uridine-5'-O-(3-thiotriphosphate) trisodium UTPγS trisodium	P2Y Receptor	Metabolic Disease
Uridine-5'-O-(3-thiotriphosphate) trisodium, a stable analogue of UTP, is a potent agonist of the *P2Y2* and *P2Y4* receptors with increased metabolic stability ^[2].

HY-13831

BPTU BMS-646786	P2Y Receptor	Neurological Disease Cancer
BPTU (BMS-646786) is a non-nucleotide *P2Y₁* receptor allosteric antagonist with antithrombotic activity. BPTU is able to block the P2Y1 receptor located at the neuromuscular junction of the gastrointestinal tract ^[2].

HY-137603

Uridine-5'-O-3-thiotriphosphate UTPγS	P2Y Receptor	Metabolic Disease
Uridine-5'-O-(3-thiotriphosphate) (UTPγS), a stable analogue of UTP, is a potent agonist of the *P2Y2* and *P2Y4* receptors with increased metabolic stability ^[2].

HY-108660

PSB-0739 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y₁₂ receptor antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect .

HY-108656

MRS2365	P2Y Receptor Arrestin	Cardiovascular Disease
MRS2365 is a potent and selective P2Y1 receptor (EC₅₀=0.4 nM) /[ ³⁵S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC₅₀ of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors ^[2] .

HY-137606

Uridine adenosine tetraphosphate UP4A	P2X Receptor	Cardiovascular Disease
Uridine adenosine tetraphosphate (UP4A) is an endothelium-derived vasoconstrictor that primarily acts through the *P2X1* receptor and possibly through the *P2Y2* and *P2Y4* receptors. Uridine adenosine tetraphosphate can be used in the study of cardiovascular diseases .

HY-131821

5'-TMPS Thymidine-5'-O-monophosphorothioate	P2Y Receptor	Others
5'-TMPS (Thymidine-5'-O-monophosphorothioate) is a selective partial agonist of *P2Y₆R* and an antagonist of *P2Y₁₄R*. Additionally, 5'-TMPS acts as a positive regulator of angiogenesis, exhibiting pro-angiogenic effects ^[2]

HY-113359AS3

Uridine 5'-diphosphate-15N2 dilithium	Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor	Others
Uridine 5'-diphosphate- ¹⁵N₂ dilithium is ¹⁵N labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-108659

NF340	P2Y Receptor	Inflammation/Immunology
NF340 is a potent and selective P2Y11 receptor antagonist. NF340 inhibits the activity of P2Y11R by completely combining with ATP-binding amino acid residues. NF340 ameliorates inflammation in human fibroblast-like synoviocytes and can be used for rheumatoid arthritis research .

HY-113359AS1

Uridine 5'-diphosphate-13C9 dilithium	Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor	Others
Uridine 5'-diphosphate- ¹³C₉ dilithium is ¹³C-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-108658

MRS2500 tetraammonium	P2Y Receptor	Cardiovascular Disease
MRS2500 tetraammonium is a potent, selective and stable antagonist of the *P2Y1* receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC₅₀ value of 0.95 nM. Antithrombotic activity ^[2] .

HY-10064

Ticagrelor 5 Publications Verification AZD6140; AR-C 126532XX	P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-101044

PPADS tetrasodium 2 Publications Verification	P2X Receptor Na+/Ca2+ Exchanger	Neurological Disease
PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC₅₀s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC₅₀~0.9 mM) and recombinant P2Y4 (IC₅₀~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca ²⁺ exchanger in guinea pig airway smooth muscle ^[2].

Cat. No.	Product Name	Type

HY-114364

UDP-Galactose disodium

Gene Sequencing and Synthesis

UDP-Galactose disodium is a natural agonist of the P2Y₁₄ receptor with an EC₅₀ of 0.67 μM for the hP2Y₁₄ receptor. UDP-Galactose disodium is a substrate for the transferase beta-1, 4 galactosyltransferase V (B4GALT5). In addition, UDP-Galactose disodium is required for the biosynthesis of several abundant glycoconjugates that form the surface glycocalyx of Leishmania major ^[2] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113044R

Uridine diphosphate glucose (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	P2Y Receptor Endogenous Metabolite
Uridine diphosphate glucose (Standard) is the analytical standard of Uridine diphosphate glucose. This product is intended for research and analytical applications. Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y₁₄ receptor, a neuroimmune system GPCR ^[2].

HY-W010832

Uridine-5'-diphosphate disodium salt 1 Publications Verification	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Inflammation/Immunology Disease Research Fields	P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite
Uridine-5'-diphosphate disodium salt is a potent, selective *P2Y₆* receptor native agonist (EC₅₀=300 nM; pEC₅₀=6.52 for human P2Y₆ receptor). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis ^[2].

HY-W013093

Uridine triphosphate trisodium salt 2 Publications Verification UTP trisodium salt; Uridine 5'-triphosphate trisodium salt	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite P2Y Receptor
Uridine triphosphate (UTP) trisodium salt is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate trisodium salt activates membrane-bound P2Y2 receptors ^[2].

HY-N7740

Adenosine 2',5'-diphosphate sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	P2Y Receptor Endogenous Metabolite
Adenosine 2',5'-diphosphate sodium is a competitive *P2Y1* antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet *P2X1* receptors ^[2].

HY-113044

Uridine diphosphate glucose	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite P2Y Receptor
Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y₁₄ receptor, a neuroimmune system GPCR ^1.

HY-113359

Uridine 5'-diphosphate	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	P2Y Receptor Endogenous Metabolite
Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor .

HY-W010820

Uridine 5'-diphosphate sodium salt	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Inflammation/Immunology	P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite
Uridine 5'-diphosphate sodium salt is a potent, selective *P2Y₆* receptor native agonist (EC₅₀=300 nM; pEC₅₀=6.52) and a potent *P2Y₁₄* antagonist (pEC₅₀=7.28). Uridine 5'-diphosphate sodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis ^[2].

HY-107372

Uridine triphosphate UTP; Uridine 5'-triphosphate	Cardiovascular Disease Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite DNA/RNA Synthesis P2Y Receptor
Uridine triphosphate (UTP) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors ^[2].

HY-150524

UDP-Galactose	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite P2Y Receptor
UDP-Galactose is a monosaccharide involved in nucleotide sugar metabolism. UDP-Galactose and its derivatives act as a natural agonist for G_i protein-conjugated P2Y₁₄ receptors in the immune system (IC₅₀=0.67 μM, hP2Y₁₄) .

HY-W013093R

Uridine triphosphate trisodium salt (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite P2Y Receptor
Uridine triphosphate (trisodium salt) (Standard) is the analytical standard of Uridine triphosphate (trisodium salt). This product is intended for research and analytical applications. Uridine triphosphate (UTP) trisodium salt is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate trisodium salt activates membrane-bound P2Y2 receptors ^[2].

HY-111557

YM-254890 Maximum Cited Publications 9 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	P2Y Receptor
YM-254890 is a selective G_αq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the *P2Y₁* signal transduction pathway, with an IC₅₀ value below 0.6 μM ^[2].

HY-114364

UDP-Galactose disodium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	P2Y Receptor Endogenous Metabolite
UDP-Galactose disodium is a natural agonist of the *P2Y₁₄* receptor with an EC₅₀ of 0.67 μM for the *hP2Y₁₄* receptor. UDP-Galactose disodium is a substrate for the transferase beta-1, 4 galactosyltransferase V (B4GALT5). In addition, UDP-Galactose disodium is required for the biosynthesis of several abundant glycoconjugates that form the surface glycocalyx of Leishmania major ^[2] .

HY-N7032

Uridine 5′-diphosphoglucose disodium salt 5 Publications Verification UDP-D-Glucose disodium salt	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite P2Y Receptor
Uridine 5’-diphosphoglucose (UDP-glucose) disodium salt, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory *P2Y14* receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium salt is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium salt is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue ^[2] .

Species:	Human (2)
Tag:	His (1) Flag (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701629

	P2Y1 Protein, Human (Sf9, FLAG) P2RY1; P2Y purinoceptor 1; P2Y1; ADP receptor; Purinergic receptor	Human	Sf9 insect cells
	The P2Y1 protein acts as a receptor for extracellular adenine nucleotides, specifically ADP. In platelets, ADP binding activates phospholipase C, leading to intracellular calcium mobilization, platelet shape changes, and aggregation. P2Y1 Protein, Human (Sf9, FLAG) is the recombinant human-derived P2Y1 protein, expressed by Sf9 insect cells , with N-Flag labeled tag. The total length of P2Y1 Protein, Human (Sf9, FLAG) is 372 a.a., .

HY-P701630

	P2Y1 Protein, Human (Sf9, FLAG, His) P2RY1; P2Y purinoceptor 1; P2Y1; ADP receptor; Purinergic receptor	Human	Sf9 insect cells
	The P2Y1 protein acts as a receptor for extracellular adenine nucleotides, specifically ADP. In platelets, ADP binding activates phospholipase C, leading to intracellular calcium mobilization, platelet shape changes, and aggregation. P2Y1 Protein, Human (Sf9, FLAG, His) is the recombinant human-derived P2Y1 protein, expressed by Sf9 insect cells , with C-10*His, N-Flag labeled tag. The total length of P2Y1 Protein, Human (Sf9, FLAG, His) is 372 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-113359AS2

Uridine 5'-diphosphate-13C9,15N2 dilithium
Uridine 5'-diphosphate- ¹³C₉, ¹⁵N₂ dilithium is ¹³C and ¹⁵N-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-N7032S1

Uridine 5′-diphosphoglucose-13C6 disodium

Uridine 5′-diphosphoglucose- ¹³C₆ (disodium) is the ¹³C labeled Uridine 5′-diphosphoglucose disodium salt[1]. Uridine 5′-diphosphoglucose disodium salt (UDP-D-Glucose disodium salt) is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine-5′-diphosphoglucose is an agonist of the P2Y14 receptor, a neuroimmune system GPCR[2].

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-113359AS3

Uridine 5'-diphosphate-15N2 dilithium
Uridine 5'-diphosphate- ¹⁵N₂ dilithium is ¹⁵N labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-113359AS1

Uridine 5'-diphosphate-13C9 dilithium
Uridine 5'-diphosphate- ¹³C₉ dilithium is ¹³C-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a *P2Y₆* receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-10064S

Ticagrelor-d7
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel[1]. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[2].

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation ^[2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83390

	P2Y12 Antibody (YA3135) HORK3; P2Y12; ADPG-R; BDPLT8; SP1999; P2T(AC); P2Y(AC); P2Y(12)R; P2Y(ADP); P2Y(cyc)	WB, IP	Human
	P2Y12 Antibody (YA3135) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3135), targeting P2Y12, with a predicted molecular weight of 39 kDa (observed band size: 52 kDa). P2Y12 Antibody (YA3135) can be used for WB, IP experiment in human background.

HY-P81946

	P2Y6 Antibody (YA1691) P2ry6; P2Y6; P2Y6 receptor; PP2891	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	P2Y6 Antibody (YA1691) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1691), targeting P2Y6, with a predicted molecular weight of 36 kDa (observed band size: 36 kDa). P2Y6 Antibody (YA1691) can be used for WB, IHC-F, IHC-P, ICC/IF, IP experiment in human background.

HY-P81901

	OXGR1 Antibody (YA1646) P2Y15; Alpha-ketoglutarate receptor 1; G-protein coupled receptor 80; G-protein coupled receptor 99; P2Y purinoceptor 15	WB	Human, Rat
	OXGR1 Antibody (YA1646) is a biotin-conjugated non-conjugated IgG antibody, targeting OXGR1, with a predicted molecular weight of 38 kDa (observed band size: 38 kDa). OXGR1 Antibody (YA1646) can be used for WB experiment in human, rat background.